联用传统合成DMARD对类风湿关节炎患者生物制剂依从性的影响:多中心人群队列研究
该研究基于加拿大五省和美国数据库的人群队列,纳入2007至2014年间起始bDMARD治疗的成年RA患者20,221例,评估联用csDMARD对bDMARD停药、换药及剂量变化的影响。结果显示联用csDMARD与bDMARD停药或换药风险无显著关联,但与bDMARD剂量较初始3个月平均剂量小幅增加相关。
要点
- 联用csDMARD未显著降低bDMARD停药风险(HR 0.90,95%CI 0.79–1.02)。
- 联用csDMARD未显著降低bDMARD换药风险(HR 0.95,95%CI 0.80–1.11)。
- 联用csDMARD与bDMARD剂量较初始3个月平均剂量小幅增加相关(+0.56% mg/day,95%CI +0.14%至+0.97%)。
核心结论
- 在加拿大和美国的大型RA队列中,联用csDMARD并未明确降低bDMARD停药、换药或增加剂量的可能性。
研究设计与样本
- 基于加拿大五省(阿尔伯塔、曼尼托巴、安大略、魁北克、萨斯喀彻温)和美国IBM MarketScan数据库的人群队列研究。
- 纳入2007年1月1日至2014年3月30日间起始bDMARD治疗、经3个月起始期后的成年RA患者20,221例。
- 采用边际结构模型分析csDMARD暴露的时间变化效应,线性回归分析剂量变化,似然比荟萃分析合并各中心结果。
主要发现
- 研究人群包括阿达木单抗7609例、依那西普9809例、阿巴西普1024例、英夫利西单抗1779例新使用者。
- 联用csDMARD与bDMARD停药风险无显著关联(HR 0.90,95%内在置信区间0.79–1.02)。
- 联用csDMARD与bDMARD换药风险无显著关联(HR 0.95,95%内在置信区间0.80–1.11)。
- 联用csDMARD与bDMARD剂量较初始3个月平均剂量小幅增加相关(平均百分比变化+0.56% mg/day,95%内在置信区间+0.14%至+0.97%)。
临床怎么用
- 对于使用bDMARD的RA患者,联用csDMARD不应仅以改善bDMARD依从性为目的。
- 临床决策联用csDMARD时需综合评估其他获益与风险,而非期望减少bDMARD停药或换药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the impact of concomitant use of conventional synthetic DMARDs (csCMARD) on adherence, switching and dose of biologic disease modifying antirheumatic drugs (bDMARD) in rheumatoid arthritis (RA) patients treated with bDMARDs. PATIENTS AND METHODS: This was a population-based cohort study conducted in five provinces of Canada (Alberta, Manitoba, Ontario, Quebec, and Saskatchewan), and one American database (IBM® MarketScan® Databases). Adult RA patients entered the study after a 3-month initiation period of bDMARDs between 1 January 2007, and 30 March 2014. Concomitant csDMARD exposure was compared to non-csDMARD exposure on the following outcomes: discontinuation of bDMARD therapy, switching of bDMARDs, and percent change in dose of bDMARD compared to initial dose. The effect of the time-varying changes in csDMARD exposure was analyzed using marginal structural models. Dose change was analyzed using linear regression. Results from each participating site were combined using likelihood ratio meta-analysis. RESULTS: The study population comprised 20,221 new users of bDMARDs: adalimumab (7609), etanercept (9809), abatacept (1024), infliximab (1779). Concomitant use of csDMARD therapy was not significantly associated with reduced discontinuation of bDMARD treatment (hazard ratio 0.90, 95% intrinsic confidence interval 0.79 to 1.02) or reduced switching of bDMARDs (hazard ratio 0.95, 95% intrinsic confidence interval 0.80 to 1.11), but was associated with a small increase in bDMARD dose compared to the mean dose over the first three months of treatment (mean percentage change in dose +0.56% mg/day, 95% intrinsic confidence interval +0.14% to +0.97%). CONCLUSION: In this large study of RA patients using bDMARDs in Canada and the United States, we found no clear evidence that patients who received concomitant csDMARD therapy were less likely to discontinue, switch or increase their dose of bDMARD.
引用
- Dormuth CR, Fisher A, Hudson M, et al. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. Semin Arthritis Rheum. 2021. PMID: 34462128. doi:10.1016/j.semarthrit.2021.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。